News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
684,203 Results
Type
Article (52519)
Company Profile (247)
Press Release (631437)
Multimedia
Podcasts (76)
Webinars (14)
Section
Business (191835)
Career Advice (2625)
Deals (34175)
Drug Delivery (118)
Drug Development (79159)
Employer Resources (161)
FDA (16357)
Job Trends (15220)
News (330311)
Policy (32689)
Tag
Academia (2867)
Academic (1)
Accelerated approval (5)
Adcomms (26)
Allergies (93)
Alliances (49662)
ALS (96)
Alzheimer's disease (1470)
Antibody-drug conjugate (ADC) (141)
Approvals (16341)
Artificial intelligence (281)
Autoimmune disease (25)
Automation (16)
Bankruptcy (347)
Best Places to Work (11959)
BIOSECURE Act (18)
Biosimilars (102)
Biotechnology (159)
Bladder cancer (84)
Brain cancer (30)
Breast cancer (284)
Cancer (2332)
Cardiovascular disease (192)
Career advice (2213)
Career pathing (34)
CAR-T (162)
Cell therapy (450)
Cervical cancer (20)
Clinical research (64395)
Collaboration (884)
Company closure (1)
Compensation (473)
Complete response letters (24)
COVID-19 (2691)
CRISPR (45)
C-suite (258)
Cystic fibrosis (90)
Data (2240)
Decentralized trials (2)
Denatured (30)
Depression (54)
Diabetes (277)
Diagnostics (6629)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (41)
Drug discovery (127)
Drug pricing (119)
Drug shortages (29)
Duchenne muscular dystrophy (97)
Earnings (71315)
Editorial (43)
Employer branding (20)
Employer resources (144)
Events (102137)
Executive appointments (766)
FDA (17659)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (777)
Gene editing (114)
Generative AI (23)
Gene therapy (327)
GLP-1 (787)
Government (4752)
Grass and pollen (6)
Guidances (67)
Healthcare (19586)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (131)
Indications (30)
Infectious disease (2845)
Inflammatory bowel disease (145)
Inflation Reduction Act (11)
Influenza (53)
Intellectual property (100)
Interviews (540)
IPO (15572)
IRA (49)
Job creations (3712)
Job search strategy (1821)
Kidney cancer (11)
Labor market (25)
Layoffs (482)
Leadership (24)
Legal (7452)
Liver cancer (78)
Lung cancer (335)
Lymphoma (152)
Machine learning (7)
Management (58)
Manufacturing (320)
MASH (75)
Medical device (14372)
Medtech (14376)
Mergers & acquisitions (19165)
Metabolic disorders (730)
Multiple sclerosis (83)
NASH (23)
Neurodegenerative disease (106)
Neuropsychiatric disorders (32)
Neuroscience (2053)
NextGen: Class of 2025 (6958)
Non-profit (4860)
Now hiring (33)
Obesity (385)
Opinion (242)
Ovarian cancer (74)
Pain (94)
Pancreatic cancer (85)
Parkinson's disease (158)
Partnered (21)
Patents (239)
Patient recruitment (115)
Peanut (51)
People (59354)
Pharmaceutical (59)
Pharmacy benefit managers (16)
Phase I (19917)
Phase II (28260)
Phase III (21444)
Pipeline (1224)
Policy (158)
Postmarket research (2591)
Preclinical (8296)
Press Release (71)
Prostate cancer (110)
Psychedelics (37)
Radiopharmaceuticals (256)
Rare diseases (395)
Real estate (6069)
Recruiting (66)
Regulatory (22682)
Reports (26)
Research institute (2530)
Resumes & cover letters (388)
Rett syndrome (5)
RNA editing (4)
RSV (41)
Schizophrenia (79)
Series A (137)
Series B (87)
Service/supplier (20)
Sickle cell disease (57)
Special edition (12)
Spinal muscular atrophy (157)
Sponsored (32)
Startups (3656)
State (2)
Stomach cancer (15)
Supply chain (73)
Tariffs (40)
The Weekly (44)
Vaccines (722)
Venture capitalists (40)
Weight loss (266)
Women's health (35)
Worklife (19)
Date
Today (133)
Last 7 days (887)
Last 30 days (2667)
Last 365 days (32985)
2025 (10903)
2024 (35489)
2023 (40170)
2022 (51197)
2021 (55616)
2020 (54647)
2019 (48713)
2018 (37042)
2017 (33069)
2016 (32400)
2015 (37580)
2014 (29511)
2013 (24958)
2012 (26905)
2011 (27586)
2010 (25502)
Location
Africa (871)
Alabama (53)
Alaska (7)
Arizona (213)
Arkansas (14)
Asia (40929)
Australia (7666)
California (5908)
Canada (2015)
China (542)
Colorado (268)
Connecticut (279)
Delaware (153)
Europe (92700)
Florida (907)
Georgia (214)
Hawaii (1)
Idaho (62)
Illinois (581)
India (27)
Indiana (324)
Iowa (11)
Japan (166)
Kansas (105)
Kentucky (27)
Louisiana (13)
Maine (61)
Maryland (920)
Massachusetts (4391)
Michigan (225)
Minnesota (388)
Mississippi (2)
Missouri (88)
Montana (30)
Nebraska (23)
Nevada (65)
New Hampshire (69)
New Jersey (1723)
New Mexico (31)
New York (1722)
North Carolina (1009)
North Dakota (9)
Northern California (2539)
Ohio (215)
Oklahoma (12)
Oregon (37)
Pennsylvania (1340)
Puerto Rico (13)
Rhode Island (34)
South America (1214)
South Carolina (24)
South Dakota (1)
Southern California (2251)
Tennessee (104)
Texas (892)
United States (22832)
Utah (183)
Virginia (149)
Washington D.C. (66)
Washington State (538)
West Virginia (3)
Wisconsin (65)
684,203 Results for "pure bioscience formerly known as innovative medical services".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
PURE Bioscience Announces a New Distribution Agreement With Hydrite Chemical Company
January 21, 2025
·
6 min read
Business
PURE Bioscience Reports Fiscal Third Quarter 2024 Financial Results
PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2024.
June 14, 2024
·
12 min read
Business
PURE Bioscience Appoints Darin Zehr to Board of Directors
PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported the appointment of Darin Zehr to its Board of Directors, effective as of May 1, 2024.
May 6, 2024
·
4 min read
Press Releases
Meridian Bioscience Congratulates Catherine Lufkin For Receiving Pure Earth’s 2025 “Force Of Nature” Award
March 6, 2025
·
4 min read
Press Releases
PURE Bioscience Reports Fiscal First Quarter 2025 Financial Results
December 16, 2024
·
8 min read
Business
PURE Bioscience Announces an International Supply and License Agreement with AgroVet Alliance
PURE Bioscience, Inc., creator of the patented non-toxic silver dihydrogen citrate antimicrobial, and AgroVet Alliance, FZE, have entered into a multi-year international supply and license agreement for the purchase and selling of SDC products under special terms and conditions.
June 18, 2024
·
6 min read
Press Releases
PURE Bioscience Announces Distribution Agreement with Quip Laboratories
November 4, 2024
·
5 min read
Business
PURE Bioscience Reports Fiscal Second Quarter 2024 Financial Results
PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2024.
March 18, 2024
·
13 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
PURE Bioscience Reports Fiscal 2024 Financial Results
October 29, 2024
·
10 min read
1 of 68,421
Next
